Cambridge-based biotechnology company 4basebio PLC (AIM: 4BB) disclosed on Wednesday that it has signed a Clinical Supply Agreement with an unnamed cancer immunotherapy developer to provide GMP-grade opDNA starting material for a Phase II clinical trial programme.

The multi-year agreement is expected to generate an approximate seven-figure revenue stream over the next 12 months and will see 4basebio supply synthetic DNA for use in the client's immunotherapy candidate.

The Cambridge-based company said its enzymatic, cell-free opDNA manufacturing platform offers a safer and more cost-effective alternative to plasmid DNA by eliminating microbial contamination and antibiotic resistance genes from the production process.

4basebio said the agreement highlights growing commercial momentum for its synthetic DNA platform across next-generation genetic medicines, including gene therapies, genome editing, mRNA production and DNA vaccines.